| 5-FU | 5-fluorouracil |
| ADCs | antibody-drug conjugates |
| BRAF CEP17 |
v-raf murine sarcoma viral oncogene homolog B1 centromere enumeration probe for chromosome 17 |
| CNS | central nervous system |
| CRC | colorectal cancer |
| ctDNA | circulating tumor DNA |
| EGF EGFR EREG |
epidermal growth factor epidermal growth factor receptor epiregulin |
| ESMO | European Society of Medical Oncology |
| FISH | fluorescence in situ hybridization |
| FOLFIRI | 5-fluouracil/leucovorin/irinotecan |
| FOLFOX | 5-fluouracil/leucovorin/oxaliplatin |
| FOLFOXIRI | 5-fluouracil/leucovorin/oxaliplatin/irinotecan |
| HER2 | human epidermal growth factor receptor 2 |
| IHC | immunochemistry |
| LV | leucovorin |
| m MAPK |
month mitogen-activated protein kinase |
| mCRC | metastatic colorectal cancer |
| mPFS | median progression-free survival |
| NCCN | National Comprehensive Cancer Network |
| NGS | next-generation sequencing |
| NK | natural killer |
| NTRK | neurotrophic tyrosine receptor kinase |
| ORR | overall response rates |
| OS PI3K |
overall survival phosphoinositide 3-kinase |
| PFS PTEN |
progression-free survival phosphatase and tensin homolog |
| QT | chemotherapy |
| RAS RTK STAT |
rat sarcoma virus receptor tyrosine kinase signal transducer and activator of transcription |
| T-DM1 | trastuzumab emastine |
| TD | trastuzumab deruxtecan |
| TKIs | tyrosine kinase inhibitors |
| VEGF | anti-vascular endothelial growth factor |
| WT | wild-type |